Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients.
Ondrej FialaJindrich FinekAlexandr PoprachBohuslav MelicharJindřich KopeckýMilada ZemanovaKaterina KopeckovaTomas MlcochTomas DolezalLenka CapkovaTomas BuchlerPublished in: Cancers (2020)
The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.